The Medicines and Healthcare products Regulatory Agency (MHRA) has revealed plans to overhaul the regulatory framework for rare disease therapies, aiming to speed up their development and availability for the approximately 3.5 million people in the UK are affected by rare diseases, about one in every 17 people.
Currently, fewer than 5% of rare diseases have approved treatments. Patients often face an average diagnostic delay of 5.6 years, with 30% of affected children dying before age five. The financial burden of delayed diagnosis and limited treatment options is substantial, costing billions annually due to health-related disability and economic loss.
The MHRA’s new regulatory proposals aim to address the unique challenges of rare disease treatments, including small, scattered patient populations and limited data, without compromising on safety. Gene-based therapies like CRISPR and mRNA offer highly personalized treatment options, even for individual patients, but the current regulatory process requiring separate approvals for clinical trials and marketing is inefficient and costly.
The paper outlines bold ideas such as issuing early, combined approval for clinical trials and marketing authorization based on compelling but limited evidence, coupled with a strict safety monitoring program and regular real-world evidence review.
The reform also calls for:
- Enhanced sharing of scarce data nationally and internationally
- Possibilities for single approvals for therapies with components personalized to individual patients
- Strengthened post-market surveillance
- Better alignment across UK, NHS, and international health systems
These changes support the Government’s Rare Disease Action Plan and NHS long-term strategies. A Rare Disease Consortium comprising patients, academics, industry, and regulators is assisting in developing and implementing the reforms.
UK health leaders emphasize the potential of these reforms to position the UK as a global leader in rare disease innovation, reducing the clinical and economic burden while improving patient access to life-changing therapies.
The MHRA remains committed to upholding rigorous standards for safety, efficacy, and quality, aiming to transform rare disease patient outcomes and support the NHS by enabling faster access to innovative treatments.
This initiative signals a landmark step toward making the UK a hub for rare disease research and therapies, offering hope to millions currently underserved by existing treatment frameworks.
Learn more: Major change for rare disease treatments on way, signals MHRA
